Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside Document date: 2016_9_20
ID: 04pp3lv0_60
Snippet: COPD is a persistent lung disease characterized by irreversible chronic airflow limitation. The disease is usually progressive and associated with an increased chronic inflammatory response in the lungs [205, 206] . It is the result of long term exposure to air pollutants and usually associated with cigarette smoking [205] . It affects around 10% of the population in the world. It is the fourth leading cause of death in most of the industrialized.....
Document: COPD is a persistent lung disease characterized by irreversible chronic airflow limitation. The disease is usually progressive and associated with an increased chronic inflammatory response in the lungs [205, 206] . It is the result of long term exposure to air pollutants and usually associated with cigarette smoking [205] . It affects around 10% of the population in the world. It is the fourth leading cause of death in most of the industrialized countries and expected to become the third by 2020 [207] . Three classes of medications used to manage COPD are bronchodilators (including β 2 -adrenergic receptor and anticholinergic drugs), corticosteroids and phosphodiesterase-4 inhibitor. They are effective in relieving the symptoms of COPD, but none of them can reverse the progressive deterioration in lung function or cure the disease [4, 205] . It is desirable to develop a novel therapy that can simultaneously control the symptoms and improve the long-term prognosis of the disease.
Search related documents:
Co phrase search for related documents- leading cause and long term prognosis: 1, 2
- leading cause and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36
- leading cause and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- leading cause and lung inflammatory response: 1, 2, 3, 4, 5, 6
- leading cause and novel therapy: 1, 2, 3, 4, 5
- long air pollutant term exposure and term exposure: 1, 2, 3, 4
- long term and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- long term and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- long term and medication class: 1, 2
- long term and novel therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- long term and symptom control: 1, 2, 3, 4, 5, 6, 7, 8, 9
- long term and term exposure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- long term and world population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- long term and world population 10: 1
- lung disease and novel therapy: 1, 2, 3, 4, 5
- lung disease and progressive deterioration: 1, 2
- lung disease and symptom control: 1
- lung disease and term exposure: 1, 2, 3, 4
- lung disease and world population: 1, 2
Co phrase search for related documents, hyperlinks ordered by date